Saizen® + Saizen®
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Idiopathic Short Stature
Conditions
Idiopathic Short Stature
Trial Timeline
Dec 1, 2012 → Mar 1, 2015
NCT ID
NCT01746862About Saizen® + Saizen®
Saizen® + Saizen® is a phase 3 stage product being developed by Merck for Idiopathic Short Stature. The current trial status is completed. This product is registered under clinical trial identifier NCT01746862. Target conditions include Idiopathic Short Stature.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01746862 | Phase 3 | Completed |
| NCT00249821 | Phase 3 | Completed |
Competing Products
20 competing products in Idiopathic Short Stature